A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902).
Ogata Y, Shimokawa M, Tanaka T, Emi Y, Oki E, Saeki H, Sadanaga N, Kusumoto T, Touyama T, Kimura M, Baba H, Akagi Y, Shirouzu K, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC).
Ogata Y, et al. Among authors: maehara y.
Int J Clin Oncol. 2016 Apr;21(2):335-343. doi: 10.1007/s10147-015-0895-3. Epub 2015 Sep 4.
Int J Clin Oncol. 2016.
PMID: 26338269
Free PMC article.
Clinical Trial.